Genitourinary Cancers Symposium Annual Meeting Coverage

Pre-Cystectomy Chemo Does Not Up Survival in 'Real World' Setting

Pre-Cystectomy Chemo Does Not Up Survival in 'Real World' Setting

Finding contrasts with results of randomized clinical trials.

Biologics Combo Shows Promise As First-Line mRCC Therapy

Biologics Combo Shows Promise As First-Line mRCC Therapy

In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.

Sunitinib Dose Escalation May Benefit mRCC Patients

Sunitinib Dose Escalation May Benefit mRCC Patients

Added progression-free survival and prolonged overall survival possible, according to investigators.

Kidney Cancer Brain Metastases Not On the Rise

Kidney Cancer Brain Metastases Not On the Rise

Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.

Single RCC Bone Metastasis Predicts Better Survival

Single RCC Bone Metastasis Predicts Better Survival

Bone surgery should be considered in patients with solitary bone metastasis and no concomitant visceral metastases, according to investigators.

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.

Adjuvant Radiation Therapy Common in MIBC

Adjuvant Radiation Therapy Common in MIBC

Survey finds that 46% of radiation oncologists have administered ART to patients with muscle-invasive bladder cancer on at least one occasion.

Post-Radical Cystectomy Survival Outcomes Predicted by Preop NLR

Post-Radical Cystectomy Survival Outcomes Predicted by Preop NLR

A neutrophil-to-lymphocyte ratio below 3.09 is associated with significantly longer overall and disease-specific survival.

Researchers Identify mCRPC Drug Sequence Offering the Best Survival

Researchers Identify mCRPC Drug Sequence Offering the Best Survival

In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.

Urologists Support Targeted Biopsy

Urologists Support Targeted Biopsy

In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.

Prostate Cancer Treatment Prolongs Survival

Prostate Cancer Treatment Prolongs Survival

Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.

Higher BMI Lowers Death Risk in Men With Advanced Prostate Cancer

Higher BMI Lowers Death Risk in Men With Advanced Prostate Cancer

In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.

Black Patients May Be Adversely Affected by Less PSA Screening

Black Patients May Be Adversely Affected by Less PSA Screening

Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.

Sign Up for Free e-newsletters